Navigation Links
Aeterna Zentaris to Present at Upcoming Canaccord Genuity 30th Annual Growth Conference 2010 on August 12
Date:8/3/2010

QUÉBEC CITY, Aug. 3 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a late-stage drug development company specialized in oncology and endocrinology, today announced that its Senior Vice President and Chief Medical Officer, Paul Blake, MD, will present a corporate overview at the upcoming Canaccord Genuity 30th Annual Growth Conference on Thursday, August 12, 2010, at 3:00 p.m. ET, in the Montreal Room of the InterContinental Boston, in Boston.

A live webcast of the presentation will be available on Aeterna Zentaris' website at www.aezsinc.com in the Investors section. A replay will also be available for a period of 30 days on the Company's website.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrinology. News releases and additional information are available at www.aezsinc.com.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
2. Aeterna Zentaris: Perifosine Data Selected for Oral Presentation at Upcoming 12th World Congress on Gastrointestinal Cancer
3. Aeterna Zentaris Announces Collaboration with Almac to Develop Therapy and Companion Diagnostic in Cancer
4. Aeterna Zentaris Receives US$12 Million on Closing of Registered Direct Offering
5. Aeterna Zentaris to Raise US$12 Million in Registered Direct Offering
6. Aeterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for AEZS-108 for the Treatment of Ovarian Cancer from the Committee for Orphan Medicinal Products of the European Medicines Agency
7. Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
8. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
9. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
10. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
11. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... Falls Church, VA (PRWEB) , ... June 30, ... ... technology, and strategy services to the federal government, announced in a paper published ... Noblis scientists uncovered a potential problem with the diagnostic techniques currently used to ...
(Date:6/30/2015)... HAUPPAUGE, N.Y. , June 30, 2015  Custom ... provider, announced today that they are silver sponsors of ... an official PCDC sponsor, Custom is lending their support ... in low-income communities. Since its founding in ... for the primary care area.  PCDC has financed over ...
(Date:6/30/2015)... ... June 30, 2015 , ... Smarter Alloys today ... revolutionary new archwire that allows orthodontists to simultaneously apply different forces to different ... of SmartArch. “We’re thrilled about taking SmartArch one step closer to commercial availability ...
(Date:6/29/2015)... , ... June 29, 2015 , ... ... B2. Under the terms of the agreement, MediVet will acquire the rights to ... (UCMSCs). MB-007 is currently in pre-clinical development as a potential next-generation treatment for ...
Breaking Biology Technology:Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 2Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 3Noblis and Government Scientists Identify New Genomic Signatures of Ebola Using Whole Genomic Sequencing and Innovative BioVelocity Analytics Tool 4Custom Computer Specialists Announces Sponsorship Of The Primary Care Development Corporation's Corporate Circle 2New case studies for SmartArch orthodontic archwire paves way to product launch later this year 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3
... DIEGO, April 11, 2011 MabVax Therapeutics, Inc., a ... development of vaccine and antibody based therapies to address ... that it has received the Phase 2 portion of ... National Cancer Institute (NCI) under the agency,s Streamlined Non-competing ...
... 8, 2011 VIGILAIR Systems, an industry ... in a newly published, and first of its kind ... Hospital Acquired Infections (HAI) with the application of VIGILAIR® ... (NICU). The published article , Effect of ...
... Inc. (OTCBB: BONU), a specialty life science technology-based company, today ... new member to its Board of Directors. ... Business, University of Pennsylvania and received his Juris Doctorate from ... in the state of New Jersey since 1971. Throughout his ...
Cached Biology Technology:MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute 2MabVax Therapeutics Receives $1.8 Million in a Phase 2 Small Business Innovation Research Program Award From the National Cancer Institute 3Newly Published Study Shows Dramatic Reduction in Hospital Acquired Infections 2BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board 2BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board 3
(Date:6/29/2015)... , June 24, 2015 ... addition of the "Latin America Biomedical Sensors Market ... their offering. The Latin America Biomedical Sensors ... a CAGR of 2.04% over the period 2014-2020 ... are adaptable to the genetic formulation of each individual. ...
(Date:6/25/2015)... , June 25, 2015 ... Market by Type (Swipe & Area), Technology, Material (Optical ... Healthcare, Commercial Security & Others) & Geography - ... marketsandmarkets, the said market is expected to reach ... 17.1%. Browse 76 market Tables ...
(Date:6/25/2015)... 2015  TAKE Solutions Ltd., a global business technology ... States Patent and Trademark Office (USPTO) for its "Method ... Solutions, Clinical Accelerators to reduce the time taken to ... standardization without the accelerators), thus reducing time to market. ... At the heart of the patented Clinical Data Standardization ...
Breaking Biology News(10 mins):Latin America Biomedical Sensors Market Report 2015-2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 2Fingerprint Sensors Market Worth $14,500.07 Million by 2020 3Fingerprint Sensors Market Worth $14,500.07 Million by 2020 4TAKE Solutions Awarded Patent By USPTO 2
... University are using nanotechnology to search for new cancer-fighting ... 10,000 times faster than current methods. The "Lab-on-Bead" ... plastic beads so small that 1,000 of them would ... a separate chemical, which can be identified later if ...
... a nutrient, sulfur is often overlooked in favor of ... its crucial role in soil condition, plant growth and ... is essential for optimizing crop yield and quality. ... Nutrition , a new book from the American Society ...
... the U.S. Supreme Court agreed to review a series of ... in submarine detection training exercises off the coast of Southern ... case this week. For many years, George Mason University ... whale strandings around the world. In his most recent paper, ...
Cached Biology News:Nanoscopic screening process to speed drug discovery 2University professor stresses links between US Navy sonar and whale strandings 2
... analysis in a modern flow cytometer, a ... are differentially labeled with fluorescent probes. However, ... used for cell labeling are broader than ... flow cytometers filters. Thus, the fluorescence signal ...
... ,Product Information , ... high quality, general purpose shaker with economical analog ... models in the line, the Orbit LS features ... Electronic controls are utilized for setting speed and ...
... GX-1000 3-D Shaker , ,Product Information ... of the GyroTwister GX-1000 is extremely efficient, ... general mixing as well as staining gels, ... continuously adjustable across a broad range. A ...
Large-capacity refrigerated incubator chamber holds up to 4 independently-operated shakers. Programmable heat, refrigeration, humidifcation are standard. Photosynthetic operation, optional....
Biology Products: